Study to Examine the Clinical Efficacy and the Nonsteroidal Anti-inflammatory Drug (NSAID)-Sparing Effect of Secukinumab Over 16 Weeks in Patients With Ankylosing Spondylitis

NCT02763046 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

211

Enrollment

INDUSTRY

Sponsor class

Conditions

Ankylosing Spondylitis

Interventions

DRUG: Secukinumab (AIN457) 150 mg s.c.
DRUG: Secukinumab (AIN457) 150 mg s.c.
DRUG: Placebo - Secukinumab (AIN457) 150 mg s.c.

Sponsor

Novartis Pharmaceuticals